Navigation Links
Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture
Date:6/30/2011

MALVERN, Pa., June 30, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced three year recurrence data from the Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX® (collagenase clostridium histolyticum) in the treatment of adult Dupuytren's contracture patients with a palpable cord. This five year observational study was designed to assess the durability of response following treatment with XIAFLEX, as well as long-term safety and progression of disease in patients from earlier Auxilium studies. At three years, the nominal recurrence rate for the 623 joints previously treated successfully with XIAFLEX was 34.8%.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

"In my opinion, the recurrence rate seen with XIAFLEX is comparable with or better than other minimally-invasive treatment options.  More importantly, the fingers I have treated with XIAFLEX do not appear to develop scar tissue, as opposed to surgically treated fingers. Scar slows recovery and complicates further treatment," said Dr. Tom Kaplan, of the Indiana Hand to Shoulder Center. "As a result, first-line use of XIAFLEX preserves all of my treatment options for those patients who do recur."

Data from the XIAFLEX Three Year Follow-upAt three years, 34.8% of joints that had achieved clinical success had experienced recurrence.  Of those patients with affected MP joints, 26.6% of joints that had achieved clinical success had recurrence through three years, while 56.4% of PIP joints that had achieved clinical success had recurrence through three years.Recurrence per protocol definition of >20 degrees or medical interventionAll Joints

MP Joints

PIP JointsPatients from all phase III studies (n=950)

1,568

92
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... PRINCETON, N.J. , Aug. 28, 2015  IP Shakti, ... Prediqtus, LLC. ... "Our new corporate identity signifies our ... the world,s first predictive analytics platform for patent claim validity." ... with the launch of the proprietary AIA Shield™ platform, the ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
(Date:8/30/2015)... ... 2015 , ... The law firm of Tomasik Kotin ... recently elected to membership in the American Board of Trial Advocates (ABOTA). ... outstanding professionalism. , ABOTA is an invitation-only, national organization comprised of judges ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Natural Rest ... beneficial effects as sleep aids and calming remedies, which help to improve mood disorders ... of a great deal of research in the field of regenerative medicine conducted by ...
(Date:8/29/2015)... ... ... Rio Salado College President Chris Bustamante announced on Aug. 19 ... Initiatives and Information Services. O’Shea, who has served Rio Salado for the last two ... through innovative technologies and strategies. , “I am very proud to be able to ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ProDrop Particles includes ... Each preset contains 15 seconds of unique footage that users can shrink and stretch ... zoom, attract and more. Users can customize color, brightness, scale, speed, range, and flare ...
Breaking Medicine News(10 mins):Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... THURSDAY, Feb. 23 (HealthDay News) -- Children with ... attention-deficit hyperactivity disorder (ADHD) and other related disorders, but ... Researchers analyzed data from more than 1,000 U.S. teens ... of psychiatric medications in those with autism, ADHD and ...
... Reinberg HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay ... but this winter,s flu season is finally here, say experts ... They report that flu activity picked up in the past ... influenza season since 1987-1988. Lab-confirmed cases of influenza have now ...
... CINCINNATI Scientists have developed a unique compound ... blood cells known to fuel ailments like cancer ... Past attempts to identify new compounds ... molecules in cells have been complicated by toxicity ...
... WEDNESDAY, Feb. 22 (HealthDay News) -- Melanoma that has spread ... but a new drug appears to double survival for those ... A mutation in the BRAF protein occurs in about ... a drug approved by the U.S. Food and Drug Administration ...
... Feb. 23 (HealthDay News) -- The first molecular evidence linking ... death could lead to new methods of diagnosis and therapy ... study suggests. Abnormal heart rhythms called ventricular arrhythmias are ... the primary cause of death from heart disease. Experts have ...
... HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay News) -- ... might just be the beginning of your spring allergies ... had warmer-than-average winter weather, which is causing trees to ... Stanley Fineman, president of the American College of Allergy, ...
Cached Medicine News:Health News:Meds for Autism Not Well Understood: Study 2Health News:Flu Season Off to a Very Late Start: CDC 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 3Health News:New Melanoma Drug May Extend Survival 2Health News:New Melanoma Drug May Extend Survival 3Health News:Study Links 'Body Clock' to Sudden Cardiac Death 2Health News:Mild Winter Heralds Early Sneezin' Season 2Health News:Mild Winter Heralds Early Sneezin' Season 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: